BCL2 and chondrosarcoma: In their review, Szuhai et al. (2012) identified several active signaling pathways for central chondrosarcoma, including pRB (61,62), IHH/PTHLH/Bcl-2 (63e66), Src, Akt, and PDGFR with no effect of imatinib, IGF, or estrogen signaling, together with hypoxic and glycolytic pathways and the overexpression of the Bcl-2 family.